Now showing items 1-12 of 12

    • Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. 

      Phi, X-A; Houssami, N; Hooning, MJ; Riedl, CC; Leach, MO; Sardanelli, F; Warner, E; Trop, I; Saadatmand, S; Tilanus-Linthorst, MMA; Helbich, TH; van den Heuvel, ER; de Koning, HJ; Obdeijn, I-M; de Bock, GH (2017-11)
      Women with a strong family history of breast cancer (BC) and without a known gene mutation have an increased risk of developing BC. We aimed to investigate the accuracy of screening using annual mammography with or without ...
    • Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. 

      Saya, S; Killick, E; Thomas, S; Taylor, N; Bancroft, EK; Rothwell, J; Benafif, S; Dias, A; Mikropoulos, C; Pope, J; Chamberlain, A; Gunapala, R; SIGNIFY Study Steering Committee; Izatt, L; Side, L; Walker, L; Tomkins, S; Cook, J; Barwell, J; Wiles, V; Limb, L; Eccles, D; Leach, MO; Shanley, S; Gilbert, FJ; Hanson, H; Gallagher, D; Rajashanker, B; Whitehouse, RW; Koh, D-M; Sohaib, SA; Evans, DG; Eeles, RA (2017-07)
      In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to ...
    • Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. 

      Ballinger, ML; Best, A; Mai, PL; Khincha, PP; Loud, JT; Peters, JA; Achatz, MI; Chojniak, R; Balieiro da Costa, A; Santiago, KM; Garber, J; O'Neill, AF; Eeles, RA; Evans, DG; Bleiker, E; Sonke, GS; Ruijs, M; Loo, C; Schiffman, J; Naumer, A; Kohlmann, W; Strong, LC; Bojadzieva, J; Malkin, D; Rednam, SP; Stoffel, EM; Koeppe, E; Weitzel, JN; Slavin, TP; Nehoray, B; Robson, M; Walsh, M; Manelli, L; Villani, A; Thomas, DM; Savage, SA (2017-12)
      Importance:Guidelines for clinical management in Li-Fraumeni syndrome, a multiple-organ cancer predisposition condition, are limited. Whole-body magnetic resonance imaging (WBMRI) may play a role in surveillance of this ...
    • Comparison of optimised endovaginal vs external array coil T2-weighted and diffusion-weighted imaging techniques for detecting suspected early stage (IA/IB1) uterine cervical cancer. 

      Downey, K; Attygalle, AD; Morgan, VA; Giles, SL; MacDonald, A; Davis, M; Ind, TEJ; Shepherd, JH; deSouza, NM (2016-04)
      OBJECTIVE:To compare sensitivity and specificity of endovaginal versus external-array coil T2-W and T2-W + DWI for detecting and staging small cervical tumours. METHODS:Optimised endovaginal and external array coil MRI at ...
    • Genetic predisposition to prostate cancer. 

      Benafif, S; Eeles, R (2016-12)
      INTRODUCTION:Prostate cancer (PrCa) is the commonest non-cutaneous cancer in men in the UK. Epidemiological evidence as well as twin studies points towards a genetic component contributing to aetiology. SOURCES OF DATA:Key ...
    • Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. 

      Seibert, TM; Fan, CC; Wang, Y; Zuber, V; Karunamuni, R; Parsons, JK; Eeles, RA; Easton, DF; Kote-Jarai, Z; Al Olama, AA; Garcia, SB; Muir, K; Grönberg, H; Wiklund, F; Aly, M; Schleutker, J; Sipeky, C; Tammela, TL; Nordestgaard, BG; Nielsen, SF; Weischer, M; Bisbjerg, R; Røder, MA; Iversen, P; Key, TJ; Travis, RC; Neal, DE; Donovan, JL; Hamdy, FC; Pharoah, P; Pashayan, N; Khaw, K-T; Maier, C; Vogel, W; Luedeke, M; Herkommer, K; Kibel, AS; Cybulski, C; Wokolorczyk, D; Kluzniak, W; Cannon-Albright, L; Brenner, H; Cuk, K; Saum, K-U; Park, JY; Sellers, TA; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Clements, JA; Spurdle, A; Teixeira, MR; Paulo, P; Maia, S; Pandha, H; Michael, A; Kierzek, A; Karow, DS; Mills, IG; Andreassen, OA; Dale, AM; PRACTICAL Consortium* (2018-01-10)
      OBJECTIVES:To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN:Analysis of genotype, PCa status, and age to ...
    • Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study. 

      Callender, T; Emberton, M; Morris, S; Eeles, R; Eeles, R; Kote-Jarai, Z; Pharoah, PDP; Pashayan, N (2019-12-20)
      BACKGROUND:The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55-69. Knowing how the potential benefits and harms of ...
    • The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. 

      Castro, E; Mikropoulos, C; Bancroft, EK; Dadaev, T; Goh, C; Taylor, N; Saunders, E; Borley, N; Keating, D; Page, EC; Saya, S; Hazell, S; Livni, N; deSouza, N; Neal, D; Hamdy, FC; Kumar, P; Antoniou, AC; Kote-Jarai, Z; PROFILE Study Steering Committee; Eeles, RA (2016-06)
      A better assessment of individualized prostate cancer (PrCa) risk is needed to improve screening. The use of the prostate-specific antigen (PSA) level for screening in the general population has limitations and is not ...
    • Prostate Cancer Germline Variations and Implications for Screening and Treatment. 

      Dias, A; Kote-Jarai, Z; Mikropoulos, C; Eeles, R (2018-09-04)
      Prostate cancer (PCa) is a highly heritable disease, and rapid evolution of sequencing technologies has enabled marked progression of our understanding of its genetic inheritance. A complex polygenic model that involves ...
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 

      Mikropoulos, C; Selkirk, CGH; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MG; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, AT; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018-01-04)
      BACKGROUND:Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition ...
    • Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. 

      Bancroft, EK; Saya, S; Page, EC; Myhill, K; Thomas, S; Pope, J; Chamberlain, A; Hart, R; Glover, W; Cook, J; Rosario, DJ; Helfand, BT; Hutten Selkirk, C; Davidson, R; Longmuir, M; Eccles, DM; Gadea, N; Brewer, C; Barwell, J; Salinas, M; Greenhalgh, L; Tischkowitz, M; Henderson, A; Evans, DG; Buys, SS; IMPACT Study Steering Committee; IMPACT Collaborators; Eeles, RA; Aaronson, NK (2019-02)
      OBJECTIVES:To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic ...
    • Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. 

      Bancroft, EK; Page, EC; Castro, E; Lilja, H; Vickers, A; Sjoberg, D; Assel, M; Foster, CS; Mitchell, G; Drew, K; Mæhle, L; Axcrona, K; Evans, DG; Bulman, B; Eccles, D; McBride, D; van Asperen, C; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Selkirk, C; Hulick, PJ; Bojesen, A; Skytte, A-B; Lam, J; Taylor, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Blanco, I; Salinas, M; Cook, J; Rosario, DJ; Buys, S; Conner, T; Ausems, MG; Ong, K-R; Hoffman, J; Domchek, S; Powers, J; Teixeira, MR; Maia, S; Foulkes, WD; Taherian, N; Ruijs, M; Helderman-van den Enden, AT; Izatt, L; Davidson, R; Adank, MA; Walker, L; Schmutzler, R; Tucker, K; Kirk, J; Hodgson, S; Harris, M; Douglas, F; Lindeman, GJ; Zgajnar, J; Tischkowitz, M; Clowes, VE; Susman, R; Ramón y Cajal, T; Patcher, N; Gadea, N; Spigelman, A; van Os, T; Liljegren, A; Side, L; Brewer, C; Brady, AF; Donaldson, A; Stefansdottir, V; Friedman, E; Chen-Shtoyerman, R; Amor, DJ; Copakova, L; Barwell, J; Giri, VN; Murthy, V; Nicolai, N; Teo, S-H; Greenhalgh, L; Strom, S; Henderson, A; McGrath, J; Gallagher, D; Aaronson, N; Ardern-Jones, A; Bangma, C; Dearnaley, D; Costello, P; Eyfjord, J; Rothwell, J; Falconer, A; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Kote-Jarai, Z; Lubinski, J; Axcrona, U; Melia, J; McKinley, J; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Wilson, P; Killick, E; IMPACT Collaborators; Moss, S; Eeles, RA (2014-09)
      Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a ...